Drug Approval | October 16, 2024
Shilpa Medicare’s CDMO customer gets fast-track designation for its investigational drug candidate
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Strokes are affecting approximately 1.8 million people annually
WHO estimates suggest that 150 million people worldwide are affected by Trachoma
WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
This is used to treat central diabetes insipidus and bedwetting
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
Enzalutamide Tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Enzalutamide Capsules will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad
Subscribe To Our Newsletter & Stay Updated
